Expression, localization and polymorphisms of the nuclear receptor PXR in Barrett's esophagus and esophageal adenocarcinoma

被引:23
|
作者
van de Winkel, Anouk [1 ]
Menke, Vivianda [1 ]
Capello, Astrid [1 ]
Moons, Leon M. G. [1 ]
Pot, Raymond G. J. [1 ]
van Dekken, Herman [2 ]
Siersema, Peter D. [1 ]
Kusters, Johannes G. [1 ]
van der Laan, Luc J. W. [3 ]
Kuipers, Ernst J. [1 ,4 ]
机构
[1] Erasmus Univ, Dept Gastroenterol & Hepatol, Med Ctr Rotterdam, Rotterdam, Netherlands
[2] Erasmus Univ, Dept Pathol, Med Ctr Rotterdam, NL-3000 DR Rotterdam, Netherlands
[3] Erasmus Univ, Dept Surg, Med Ctr Rotterdam, Rotterdam, Netherlands
[4] Erasmus Univ, Dept Internal Med, Med Ctr Rotterdam, Rotterdam, Netherlands
关键词
PREGNANE-X-RECEPTOR; BILE-ACIDS; GASTROESOPHAGEAL-REFLUX; PROMISCUOUS REGULATOR; XENOBIOTIC RECEPTOR; GENE-EXPRESSION; RISK-FACTOR; TRANSPORTERS; DEFINES; IDENTIFICATION;
D O I
10.1186/1471-230X-11-108
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The continuous exposure of esophageal epithelium to refluxate may induce ectopic expression of bile-responsive genes and contribute to the development of Barrett's esophagus (BE) and esophageal adenocarcinoma. In normal physiology of the gut and liver, the nuclear receptor Pregnane x Receptor (PXR) is an important factor in the detoxification of xenobiotics and bile acid homeostasis. This study aimed to investigate the expression and genetic variation of PXR in reflux esophagitis (RE), Barrett's esophagus (BE) and esophageal adenocarcinoma. Methods: PXR mRNA levels and protein expression were determined in biopsies from patients with adenocarcinoma, BE, or RE, and healthy controls. Esophageal cell lines were stimulated with lithocholic acid and rifampicin. PXR polymorphisms 25385C/T, 7635A/G, and 8055C/T were genotyped in 249 BE patients, 233 RE patients, and 201 controls matched for age and gender. Results: PXR mRNA levels were significantly higher in adenocarcinoma tissue and columnar Barrett's epithelium, compared to squamous epithelium of these BE patients (P < 0.001), and RE patients (P = 0.003). Immunohistochemical staining of PXR showed predominantly cytoplasmic expression in BE tissue, whereas nuclear expression was found in adenocarcinoma tissue. In cell lines, stimulation with lithocholic acid did not increase PXR mRNA levels, but did induce nuclear translocation of PXR protein. Genotyping of the PXR 7635A/G polymorphism revealed that the G allele was significantly more prevalent in BE than in RE or controls (P = 0.037). Conclusions: PXR expresses in BE and adenocarcinoma tissue, and showed nuclear localization in adenocarcinoma tissue. Upon stimulation with lithocholic acid, PXR translocates to the nuclei of OE19 adenocarcinoma cells. Together with the observed association of a PXR polymorphism and BE, this data implies that PXR may have a function in prediction and treatment of esophageal disease.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Expression, localization and polymorphisms of the nuclear receptor PXR in Barrett's esophagus and esophageal adenocarcinoma
    Anouk van de Winkel
    Vivianda Menke
    Astrid Capello
    Leon MG Moons
    Raymond GJ Pot
    Herman van Dekken
    Peter D Siersema
    Johannes G Kusters
    Luc JW van der Laan
    Ernst J Kuipers
    BMC Gastroenterology, 11
  • [2] Nuclear localization of Toll-like receptor 5 in Barrett’s esophagus and esophageal adenocarcinoma is associated with metastatic behavior
    Olli Helminen
    Heikki Huhta
    Joni Leppänen
    Joonas H Kauppila
    Heikki Takala
    Petri P Lehenkari
    Juha Saarnio
    Tuomo J Karttunen
    Virchows Archiv, 2016, 469 : 465 - 470
  • [3] Nuclear localization of Toll-like receptor 5 in Barrett's esophagus and esophageal adenocarcinoma is associated with metastatic behavior
    Helminen, Olli
    Huhta, Heikki
    Leppanen, Joni
    Kauppila, Joonas H.
    Takala, Heikki
    Lehenkari, Petri P.
    Saarnio, Juha
    Karttunen, Tuomo J.
    VIRCHOWS ARCHIV, 2016, 469 (04) : 465 - 470
  • [4] Barrett's esophagus and esophageal adenocarcinoma
    Sarisley, Christine
    GASTROENTEROLOGY NURSING, 2008, 31 (01) : 76 - 77
  • [5] Barrett's Esophagus and Esophageal Adenocarcinoma
    Bresalier, Robert S.
    ANNUAL REVIEW OF MEDICINE, 2009, 60 : 221 - 231
  • [6] Barrett's Esophagus and esophageal Adenocarcinoma
    Bloemer, M.
    Jaehne, J.
    CHIRURG, 2013, 84 (03): : 232 - 232
  • [7] MicroRNA Expression Signatures in Barrett's Esophagus and Esophageal Adenocarcinoma
    Yang, Hushan
    Gu, Jian
    Wang, Kenneth K.
    Zhang, Wei
    Xing, Jinliang
    Chen, Zhinan
    Ajani, Jaffer A.
    Wu, Xifeng
    CLINICAL CANCER RESEARCH, 2009, 15 (18) : 5744 - 5752
  • [8] Polymorphisms in genes in the androgen pathway and risk of Barrett's esophagus and esophageal adenocarcinoma
    Ek, Weronica E.
    Lagergren, Katarina
    Cook, Michael
    Wu, Anna H.
    Abnet, Christian C.
    Levine, David
    Chow, Wong-Ho
    Bernstein, Leslie
    Risch, Harvey A.
    Shaheen, Nicholas J.
    Bird, Nigel C.
    Corley, Douglas A.
    Hardie, Laura J.
    Fitzgerald, Rebecca C.
    Gammon, Marilie D.
    Romero, Yvonne
    Liu, Geoffrey
    Ye, Weimin
    Vaughan, Thomas L.
    MacGregor, Stuart
    Whiteman, David C.
    Westberg, Lars
    Lagergren, Jesper
    INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (05) : 1146 - 1152
  • [9] Chemoprevention in Barrett's esophagus and esophageal adenocarcinoma
    Alkhayyat, Motasem
    Kumar, Prabhat
    Sanaka, Krishna O.
    Thota, Prashanthi N.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
  • [10] Focus on Barrett's esophagus and esophageal adenocarcinoma
    Paulson, TG
    Reid, BJ
    CANCER CELL, 2004, 6 (01) : 11 - 16